fbpx

Mantle Cell Lymphoma- Lenalidomide, Rituxan plus Integrative Therapies

Share Button

“Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma (MCL)”

The article linked below could be talking about a blood cancer called multiple myeloma as easily as it is talking about mantle cell lymphoma.

Both blood cancers affect the same age group (65-70), both blood cancers have a five-year survival rate of 48%-50% and according to the article below both blood cancers respond to lenalidomide aka Revlimid. Autologous stem cell transplantation is also a common therapy for each cancer.

Which is why the study below caught my eye. I am both a long-term MM survivor and cancer coach. Study after study for these two blood cancers plays down the importance of collateral damage aka side effects. Not only do I live with a host of side effects incurred during my years of conventional therapies, I have remained in CR from my MM by living an evidence-based, non-toxic, anti-MM lifestyle.

I’m not saying that the newly diagnosed CML patient should ignore conventional (FDA approved) therapies. I am saying that nutrition, supplementation, and lifestyle can enhance chemotherapy while moderating toxicity.

Please watch the free webinar linked on the right side of this page. If you have any questions or comments please scroll down the page and post a question or comment. I will reply to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL 

“Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma (MCL),..

Patients treated with the agents saw a high rate of complete responses (64% CR, 92% overall response) and patients were able to achieve minimal residual disease (MRD) negativity with durable remissions beyond 4 years…
Lenalidomide was administered at 20 mg daily on days 1-21 of a 28-day cycle for 12 cycles during induction, followed by dose reduction to 15 mg during maintenance
Adverse events (AEs) during maintenance were asymptomatic grade 3-4 cytopenias including neutropenia (42%), thrombocytopenia (5%), and anemia (3%). Grade 1-2 AEs included upper respiratory infection (45%), urinary tract infection (21%), sinusitis (13%), and cellulitis (11%), which were managed in outpatient settings…
Secondary malignancies were seen in 6 patients, 15%…

Leave a Comment: